MorphoSys AG announced the completion of the first part of a phase 1 clinical study in healthy volunteers with the investigational drug candidate MOR107 ahead of schedule. MOR107 is a selective agonist of the angiotensin II receptor type 2 (AT2-R), and is a lanthipeptide based on the proprietary technology platform of MorphoSys's subsidiary Lanthio Pharma. MOR107 is also the first lanthipeptide in MorphoSys's clinical pipeline
Based on an initial analysis of subjects enrolled to date, in all doses tested in this first-in-human trial, based on blinded data, there were no clinically relevant safety events seen, and all adverse events observed thus far were mild and transient in nature. Moreover a dose-dependent pharmacokinetic profile for MOR107 was observed.
"We are very pleased with the initial data from the first part of the phase 1 clinical study of our MOR107 lanthipeptide in healthy volunteers conducted by our subsidiary Lanthio Pharma", commented Dr. Malte Peters, chief development officer of MorphoSys AG. "Preparations for the second part of the trial are ongoing."
The study has been conducted by MorphoSys's fully owned subsidiary Lanthio Pharma B.V., Groningen, Netherlands.
Morphosys completes, lanthipeptide mor107
5.png)
